<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03368742</url>
  </required_header>
  <id_info>
    <org_study_id>GX1001</org_study_id>
    <nct_id>NCT03368742</nct_id>
  </id_info>
  <brief_title>Microdystrophin Gene Transfer Study in Adolescents and Children With DMD</brief_title>
  <acronym>IGNITE DMD</acronym>
  <official_title>A Randomized, Controlled, Open-label, Single-ascending Dose, Phase I/II Study to Investigate the Safety and Tolerability, and Efficacy of Intravenous SGT-001 in Male Adolescents and Children With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solid Biosciences, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Solid Biosciences, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled, open-label, single-ascending dose study to evaluate the
      safety, tolerability and efficacy of SGT-001 in adolescents and children with Duchenne
      muscular dystrophy (DMD). Eligible patients will be randomized to an active treatment group
      or an untreated control group. Patients in the active treatment group will receive a single
      intravenous (IV) infusion of SGT-001 and will be followed for approximately 2 years. Patients
      in the untreated control group who continue to meet treatment criteria will receive SGT-001
      after 1 year on study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Active treatment group vs untreated control group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in microdystrophin protein in muscle biopsies (active treatment group)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of clinical laboratory abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of abnormalities in vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of abnormalities in physical examinations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of abnormalities on ECGs</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>SGT-001 - Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of SGT-001 at starting dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SGT-001 - Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of SGT-001 at next ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SGT-001 - Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of SGT-001 at selected dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Untreated control group. After 1 year, treatment-eligible control patients will receive SGT-001 at the selected dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SGT-001</intervention_name>
    <description>AAV9 vector containing muscle-specific promoter and microdystrophin construct</description>
    <arm_group_label>SGT-001 - Dose Level 1</arm_group_label>
    <arm_group_label>SGT-001 - Dose Level 2</arm_group_label>
    <arm_group_label>SGT-001 - Dose Level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established clinical diagnosis of DMD and documented dystrophin gene mutation
             predictive of DMD phenotype

          -  Confirmed absence of dystrophin as determined by muscle biopsy (ambulatory patients)

          -  Anti-AAV9 antibodies below protocol-specified thresholds

          -  Stable cardiac and pulmonary function

          -  Adolescents: non-ambulatory by protocol-specified criteria

          -  Children: ambulatory by protocol-specified criteria

          -  Stable daily dose of oral corticosteroids ≥ 24 wks

        Exclusion Criteria:

          -  Prior or ongoing medical condition or physical examination, ECG or laboratory findings
             that could adversely affect subject safety, compromise completion of treatment and
             follow-up, or impair assessment of study results

          -  Abnormal liver function

          -  Abnormal renal function

          -  Clinically significant coagulation abnormalities

          -  Impaired cardiovascular function based on cardiac MRI or ECHO

          -  Impaired respiratory function based on FVC % predicted or need for daytime ventilatory
             support

          -  Significant spinal deformity or presence of spinal rods

          -  Body mass index ≥ 95th percentile for age

          -  Exposure to another investigational drug within 3 months or 5 half-lives prior to
             screening

          -  Exposure to drugs affecting dystrophin or utrophin expression within 6 months prior to
             screening

        Additional inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Genevieve A. Laforet, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Solid Biosciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge A. Quiroz, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Solid Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Salabarria</last_name>
      <phone>352-273-6582</phone>
      <email>SGT001Inquiries@peds.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Barry Byrne, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

